SCHEMBL20702995

SCHEMBL20702995

CCOC(=O)C(Cn1cccn1)OC(=O)NC1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 4/20 0.60
GRM5 P41594 1/20 0.41
IDH1 O75874 1/20 0.39
FAAH O00519 5/20 0.38
ALDH1A1 P00352 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
EPHX2 P34913 1/20 0.36
CASP6 P55212 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20703287 0.99 NLRP3 (0.59) NLRP3GRM5IDH1FAAHALDH1A1
SCHEMBL23118096 0.99 NLRP3 (0.59) NLRP3GRM5IDH1FAAHALDH1A1
SCHEMBL20703068 0.87 NLRP3 (0.56) NLRP3ALDH1A1L3MBTL1
SCHEMBL20702626 0.76 NLRP3 (0.74) NLRP3GRM5HSD17B10
SCHEMBL30595469 0.76 NLRP3 (0.43) NLRP3ALDH1A1L3MBTL1
SCHEMBL20702742 0.75 NLRP3 (1.00) NLRP3
SCHEMBL23138980 0.75 NLRP3 (1.00) NLRP3
SCHEMBL20702643 0.75 NLRP3 (1.00) NLRP3
SCHEMBL16029636 0.74 NLRP3 (0.51) NLRP3ALDH1A1KDM4EHSD17B10L3MBTL1
SCHEMBL20703074 0.74 NLRP3 (0.82) NLRP3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2025-07-10 US disclosed
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NodThera Limited (GB) 2025-03-11 US disclosed
CN-111356680-B Selective inhibitors of NLRP3 inflammasome 诺瑟拉有限公司 2023-11-28 CN disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed
CN-111356680-A Selective inhibitors of NLRP3inflammasome 诺瑟拉有限公司 2020-06-30 CN disclosed
EP-3661921-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME Nodthera Limited (GB) 2020-06-10 EP disclosed
WO-2019025467-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2019-02-07 WO disclosed
WO-2019025467-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NLRP3, NOD1, NLRP1 NLRP3 1/4885GRM5 3824/4885IDH1 2389/4885
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 NLRP3 1/4885GRM5 3824/4885IDH1 2389/4885
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 NLRP3 1/4885GRM5 3824/4885IDH1 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.